- WuXi Diagnostic Investment (Cayman) Limited, a Shangai, China-based diagnostics company, completed US$150m in series B funding
- Backers also included new investors Thermo Fisher Scientific Inc., Shiyu Capital, ABC International Holdings Limited, Sunland Capital and CCBI Tech Venture
- The company also intends to use the funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline
- WuXi Diagnostics also focuses on integrated diagnostics via an open-access innovation enabling platform, centered on multi-omics clinical data from multidisciplinary technologies
- WXDX is establishing an open-access enabling platform, with multidisciplinary technologies, clinical big data and algorithms to continuously launch innovative diagnostic services
- The company has its headquarters and a CAP-accredited Independent Clinical Laboratory in Shanghai
